All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Does prior use of checkpoint inhibitors impact allo-SCT outcomes for patients with Hodgkin lymphoma?

Apr 6, 2022
Learning objective: After reading this article, learners will be able to cite a new clinical development in lymphoma/CLL

During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub was pleased to speak with Miguel-Angel Perales, Memorial Sloan Kettering Cancer Center, New York, US. We asked, Does prior use of checkpoint inhibitors impact allogeneic stem cell transplantation outcomes for patients with Hodgkin lymphoma?

Does prior use of checkpoint inhibitors impact allo-SCT outcomes for patients with Hodgkin lymphoma?

Perales begins by discussing the new therapies that have become available in the past decade to treat Hodgkin lymphoma, such as rituximab and checkpoint inhibitors. This is followed by a summary of the joint study between the Center for International Blood and Marrow Transplant Research (CIBMTR) and EBMT, which aimed to investigate if receiving a checkpoint inhibitor prior to allogeneic transplant impacted progression-free and overall survival in patients with Hodgkin lymphoma. Perales finishes by discussing the importance of having a curative approach available.